Becton Dickinson and Company (BDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Becton Dickinson and Company stock (BDX) is currently trading at $154.13. Becton Dickinson and Company PE ratio is 25.56. Becton Dickinson and Company PS ratio (Price-to-Sales) is 2.55. Analyst consensus price target for BDX is $197.15. WallStSmart rates BDX as Hold.
- BDX PE ratio analysis and historical PE chart
- BDX PS ratio (Price-to-Sales) history and trend
- BDX intrinsic value — DCF, Graham Number, EPV models
- BDX stock price prediction 2025 2026 2027 2028 2029 2030
- BDX fair value vs current price
- BDX insider transactions and insider buying
- Is BDX undervalued or overvalued?
- Becton Dickinson and Company financial analysis — revenue, earnings, cash flow
- BDX Piotroski F-Score and Altman Z-Score
- BDX analyst price target and Smart Rating
Becton Dickinson and Company
📊 No data available
Try selecting a different time range
BDX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Becton Dickinson and Company (BDX)
BDX trades at a significant discount to its Graham intrinsic value of $282.20, offering a 36% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Becton Dickinson and Company (BDX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/book. Concerns around return on equity and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Becton Dickinson and Company (BDX) Key Strengths (5)
96.08% of shares held by major funds and institutions
Large-cap company with substantial market presence
Good growth relative to its price
Trading at 1.76x book value, attractively priced
Strong earnings growth at 28.60% per year
Supporting Valuation Data
Becton Dickinson and Company (BDX) Areas to Watch (5)
Revenue growing slowly at 1.60% annually
Low profitability relative to shareholder equity
Thin operating margins with cost pressures present
Thin profit margins with limited profitability
Revenue is fairly priced at 2.55x sales
Supporting Valuation Data
Becton Dickinson and Company (BDX) Detailed Analysis Report
Overall Assessment
This company scores 61/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 8.6/10) while 5 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, PEG Ratio. Valuation metrics including PEG Ratio (1.18), Price/Book (1.76) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 28.60%.
The Bear Case
The primary concerns are Revenue Growth, Return on Equity, Operating Margin. Some valuation metrics including Price/Sales (2.55) suggest expensive pricing. Growth concerns include Revenue Growth at 1.60%, which may limit upside. Profitability pressure is visible in Return on Equity at 6.96%, Operating Margin at 13.40%, Profit Margin at 8.01%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 6.96% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (Revenue Growth, Return on Equity). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Becton Dickinson and Company (BDX) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Becton Dickinson and Company is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 21.9B with 160% growth year-over-year. Profit margins are thin at 8.0%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 160% YoY, reaching 21.9B. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
ROE of 696.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Margin expansion: can Becton Dickinson and Company push profit margins above 15% as the business scales?
Growth sustainability: can Becton Dickinson and Company maintain 160%+ revenue growth, or will competition slow it down?
Debt management: total debt of 19.5B is significantly higher than cash (1.0B). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Becton Dickinson and Company.
Bottom Line
Becton Dickinson and Company is a high-conviction growth story with revenue accelerating at 160% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 8.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(28 last 3 months)
| Insider | Type | Shares |
|---|---|---|
FELD, MICHAEL EVP, Chief Revenue Officer | Sell | -75 |
| Insider | Type | Shares |
|---|---|---|
SCOTT, BERTRAM L Director | Sell | -953 |
| Insider | Type | Shares |
|---|---|---|
BECTON, DICKINSON & CO 10% Owner | Sell | -284,771,350 |
| Insider | Type | Shares |
|---|---|---|
FELD, MICHAEL EVP, CRO & Pres. Life Sciences | Sell | -75 |
| Insider | Type | Shares |
|---|---|---|
SPIKNER, PAMELA L. SVP Controller & CAO | Sell | -84 |
| Insider | Type | Shares |
|---|---|---|
SHAN, DAVID EVP and Chief ISC Officer | Sell | -44 |
| Insider | Type | Shares |
|---|---|---|
FELD, MICHAEL EVP, CRO & Pres. Life Sciences | Sell | -74 |
Data sourced from SEC Form 4 filings
Last updated: 9:44:32 AM
About Becton Dickinson and Company(BDX)
NYSE
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.